The following LIMR-developed IP and technologies are available for licensing. To learn more, please contact LIMR at 484.476.8000 or email firstname.lastname@example.org.
Principal investigator: Janet Sawicki, PhD
Taking a new precision medicine approach, LIMR researchers have developed a safe and effective nanocarrier-based therapy that specifically targets ovarian tumor cells and blocks a central mechanism of drug resistance (siHuR-3DNA). Preclinical proof of concept suggests that targeting this mechanism via this nanocarrier agent may offer safe and effective treatment of a variety of solid tumors exhibiting drug resistance.
Therapeutics that block polyamine action, suppress tumor growth
Principal investigator: Susan Gilmour, PhD
Polyamines are ubiquitous, small molecules that are essential for all cell growth and proliferation. Tumors maintain dramatically elevated levels of polyamines to support their growth and survival. A novel class of proprietary polyamine-transport inhibitors has been shown by Dr. Gilmour to suppress tumor growth in preclinical studies. These inhibitors not only deprive tumor cells of polyamines, they also relieve polyamine-mediated immunosuppression in the tumor microenvironment.
Principal investigator: Alexander Muller, PhD
LIMR’s technology encompasses new uses of IDO inhibitors to enhance the activity of anti-angiogenic or antimetabolic drugs used to treat cancer or in other disease settings where ablation of a pathogenic blood vasculature is desired.
Principal investigator: U. Margaretha Wallon, PhD
Nausea after chemotherapy is a much-feared side effect. Yet not all patients experience it to the same degree, or even at all. Dr. Wallon developed a blood-based assay that can predict which patients will experience post-chemotherapy nausea. With that information, physicians can prescribe the right dosage of antiemetics to the right patients at the right time for a truly precision-medicine approach to patient treatment.
LIMR’s collaborative team has created the first pro-drug class of small molecule inhibitors that can be tuned to inhibit various subsets of the known IDO/TDO enzymes, representing new structure of matter for clinical development.
Building on long-standing studies of the disease-promoting small GTPase RhoB, including in selectively driving production of autoantibodies, LIMR scientists have developed a cell-permeable anti-RhoB antibody that exhibits therapeutic efficacy in preclinical models of rheumatoid arthritis, lupus and diabetes. In principle, this invention affords a general strategy for treating autoimmune disorders driven by autoantibody production as a single class by administering a single biologic agent directed against a nodal signal transduction modifier. LIMR’s innovative approach incorporates the leading edge in targeting intracellular antigens generally considered inaccessible to antibody-based therapies.
Principal investigator: Sunil Thomas, PhD
Building on their expertise in tissue barrier functions of the gastrointestinal tract, LIMR scientists have now developed an antibody-based therapy that inactivates a molecule that facilitates gut inflammation in the setting of IBD.
The immunomodulatory enzyme IDO2, discovered by LIMR scientists, has been identified as an essential mediator of autoimmune disease. In preclinical models of rheumatoid arthritis (RA), systemic administration with a cell-permeable monoclonal antibody developed at LIMR that specifically binds IDO2 in B cells reduced the level of autoreactive T and B cell activation and alleviated pathogenic symptoms. LIMR’s investigators have defined a pathway that allows for effective targeting of intracellular antigens previously considered inaccessible to antibody-based therapies.
Principal investigator: Thomas Stamato, PhD
With no well-established standards to accurately diagnose IBD, there is a need for biomarkers that are cost-effective, rapid and provide insight into individual disease complexity and biology. In addressing the need for a non-invasive assessment of IBD in patients presenting with IBS, LIMR scientists have developed a blood test that may make this determination as an aid to improving personalized care.
Monoclonal antibody cloning
Mammalian antibody display technology
Principal investigator: Scott Dessain, MD, PhD
The Center for Human Antibody Technology (CHAT) is a facility at LIMR that uses a powerful human antibody cloning platform technology developed by Dr. Dessain. CHAT uses this platform along with a state-of-the-art, high throughput antibody production and screening facility to produce human antibodies for use in the treatment of infectious disease, cancer and neurological illnesses. CHAT can help academic investigators create their own human antibody therapeutics.
LIMR researchers have defined new medicinal uses for two classes of drugs that could treat ocular diseases such as wet macular degeneration, diabetic retinopathy, macular edema, diabetic macular edema, and myopic choroidal neovascularization.